Patients at Henry Ford Hospital now have a new cancer treatment available that offers an alternative cancer surgery, without the incision or hospital stay, treating patients in 15 minutes or less and returning them to their everyday lives.
The Edge™ Radiosurgery Suite is designed to perform advanced, non-invasive cancer procedures anywhere in the body – including the brain, spine, head and neck, adrenal gland, lung, liver and pancreas – with extreme precision and low toxicity.
It is the first unit in North America and only available at the Josephine Ford Cancer Institute at Henry Ford Hospital.
The Edge, created by Varian Medical Systems, uses new real-time tumor tracking technology and motion management capabilities, improving both safety and comfort for patients by protecting healthy tissue with sub-millimeter-accuracy. And its “cutting edge” beam offers the agility to treat tumors that may be difficult to reach surgically.
Treatments are typically outpatient and completed within the same week – with only one to five sessions.
Patients will begin treatment using the Edge this week at Henry Ford Hospital.
A pioneer in the use stereotactic radiation therapy, Henry Ford’s Department of Radiation Oncology has treated more than 4,000 patients using this specialized type of stereotactic radiation therapy.
And now, the Edge offers patients:
• Faster treatment: With a dose rate of up to 2,400 monitor units per minute, it offers rapid stereotactic treatments in only 10-20 minutes compared to other systems that can take well over an hour per session.
• Increased comfort: The six degrees (6D) of freedom treatment couch provides the accuracy, precision and flexibility needed to optimally position and adjust patients, allowing them to be comfortable and breathe freely during treatment.
• Real-time imaging: An advanced motion management package makes it possible to better compensate for tumor motion during treatment. The 2.5mm multi-leaf collimator provides a distinct cutting “edge” for radiosurgery treatments.
• Cost-effective medicine: The Edge can accurately treat the vast majority of what a proton beam center can do at a fraction of the cost of a proton unit.
“Henry Ford’s Department of Radiation Oncology has a long tradition of expertise with the most advanced radiation technologies, a heritage that will now continue with the addition the Edge,” says Benjamin Movsas, M.D., Chair of the Department of Radiation Oncology at Henry Ford.
“The Edge truly represents a novel platform in radiosurgery, offering a system that provides a fully-integrated solution for planning and administering radiosurgery treatments.”
“In radiosurgery, millimeters matter,” says neurosurgeon Steven N. Kalkanis, M.D., director of the Center for Cancer Surgery at Henry Ford. “The Edge radiosurgery suite is calibrated for sub-millimeter accuracy. That will help us rest assured that we are doing everything possible to protect normal tissues.”
Henry Ford Hospital was selected by Varian as the first site for the Edge in North American because it “represents and embodies clinical excellence and we are thrilled that we get to launch this exciting new platform into clinical use with them,” according to Chris Toth, vice president of marketing for Varian’s Oncology Systems business.
Henry Ford joins Champalimaud Foundation in Lisbon, Portugal, as the first two sites in the world with the Edge.
What is Stereotactic Radiation?
Stereotactic radiation is a procedure that precisely delivers intense radiation doses to tumor targets in one to five treatments. The goal of this non-invasive procedure is to destroy, or make inactive, the tumor while minimizing dose exposure to the surrounding healthy tissue.
The Latest on: Stereotactic Radiation
[google_news title=”” keyword=”Stereotactic Radiation” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Stereotactic Radiation
- American Shared Hospital Services Announces Closing of Acquisition of 60% Majority Interest in Three Radiation Therapy Cancer Centers in Rhode Islandon May 9, 2024 at 3:01 pm
Adds $9-$10 million in Annual Revenue with Positive Net Income Contribution -- Acquisition more than Doubles Backlog to over $210 million - - ...
- Radiotherapy with hormone therapy can help some advanced prostate cancer patients avoid chemotherapyon May 8, 2024 at 10:51 pm
Radiotherapy can be used alongside hormone treatment, delaying the need for chemotherapy and therefore significantly protecting their quality of life for some patients with advanced prostate cancer, ...
- New trial finds radiotherapy combined with hormone therapy can help some advanced prostate cancer patients avoid chemotherapyon May 8, 2024 at 4:22 am
Radiotherapy can be used alongside hormone treatment, delaying the need for chemotherapy and therefore significantly protecting their quality of life for some patients with advanced prostate cancer, ...
- American Shared Hospital Services Announces First Quarter 2024 Earnings Conference Callon May 7, 2024 at 4:00 am
SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy ...
- Prostate cancer hope as patients could get painless treatment instead of chemoon May 6, 2024 at 1:33 pm
Currently patients with a form of the disease which has spread to one or two other parts of the body are assumed to be resistant to milder hormone therapy drugs ...
- Stereotactic Radiosurgery to Treat 15-Plus Brain Metastases?on April 30, 2024 at 7:27 am
A large study supports the use of stereotactic radiosurgery in patients with 15 or more brain metastases, finding improved cognitive outcomes and comparable survival to whole brain radiation.
- Amethyst Radiotherapy completes major upgrade at Queen Squareon April 29, 2024 at 4:35 am
Cancer treatment provider Amethyst Radiotherapy has installed new Gamma Knife technology at The Queen Square Radiosurgery Centre in London.
- Radiotherapy articles from across Nature Portfolioon April 28, 2024 at 5:00 pm
Here the authors report the results of a phase 1b trial of neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable HCC.
- Science & Medicine: Revolutionizing prostate cancer treatmenton April 27, 2024 at 8:59 am
Prostate cancer is the most common cancer diagnosed in men, and the five year survival rate is 97%.
- Emerging Application of Stereotactic Body Radiation Therapy for Gynecologic Malignancieson April 22, 2024 at 4:59 pm
Stereotactic body radiation therapy distinguishes itself from other techniques of radiotherapy in its requirements of more rigid patient immobilization, respiratory motion control, sophisticated ...
via Bing News